by the ceo rare diseases specialty pharmaceuticals products market operations board of directors corporate governance corporate responsibility contacts and addresses sobi s history patients patients therapy areas medical contacts patients organisations our websites research development pipeline investigator sponsored studies partnering partnering healthcare professionals healthcare professionals products by therapy area products alphabetical list medical contacts our websites investors & media investors & media press releases & news financial reports presentations web & audio casts the share financial calendar image bank rights issue 2011 careers a new chapter of our story sobi s annual report 2015 is now available online click here to read about sobi s eventful year sobi has been involved in the development and manufacturing ofrecombinant protein drugssince the technology was first developed more than30 years ago . we want to make a differenceto people with rare diseases . by working closely with patients and their relatives we learn about their daily challenges and needs . products sobi has a diversified and growth oriented commercial product portfolio within three business lines . to products transparency sobi supports transparency initiatives including the european federation of pharmaceutical industries and associations efpia disclosure code in europe and the physician payments sunshine act in the united states sunshine act . read more annual general meeting 2016 the annual general meeting in swedish orphan biovitrum ab publ reg . no. 556038 9321 was held on tuesday may 24 2016 at 3.00 p.m. at the royal swedish academy of engineering sciences iva grev turegatan 16 stockholm sweden . read more presentation of sobi s interim report january june 2016 15 july 2016 revenues for the quarter totalled sek 1 469 m 764 an increase of 92 per cent . interim report january june 2016annual report 2015annual report 2015 onlinefinancial report archive share price sek101 .40 sek 0.10 procent 0.10 % volume 684 992 ticker sobi list sse large more about the share news news reports reports show all news press releases invitation presentation of sobi s third quarter results 2016 2016 10 13 09 00 in press releases european commission approves transfer of marketing authorisation for alprolix to sobi 2016 10 03 15 30 in press releases alprolix obtains reimbursement across the united kingdom 2016 09 26 08 30 in press releases milan zdravkovic joins sobi as senior vice president head of research & development 2016 09 26 08 00 in press releases patients suffering from rare conditions should be entitled to the same quality of treatment as other patients 2013 02 27 16 32 inform genomics announces results of study predicting risk of oral mucositis in patients undergoing high dose chemotherapy 2012 04 18 16 38 gentium appoints swedish orphan biovitrum ab as exclusive distributor of defibrotide in nordic and baltic territories 2012 01 09 15 15 pharming grants sobi additional territories for the commercialization of ruconest 2011 08 29 11 06 invitation presentation of sobi s third quarter results 2016 2016 10 13 09 00 european commission approves transfer of marketing authorisation for alprolix to sobi 2016 10 03 15 30 alprolix obtains reimbursement across the united kingdom 2016 09 26 08 30 milan zdravkovic joins sobi as senior vice president head of research & development 2016 09 26 08 00 more news sobi interim report q2 2016 pdf format 2.15 mb sobi interim report q1 2016 pdf format 1.93 mb sobi q4 and full year report 2015 pdf format 3.36 mb sobi interim report q3 2015 pdf format 3.36 mb more reports more events contact swedish orphan biovitrum ab publ se 112 76 stockholm swedenphone 46 8 697 20 00 reg.no . 556038 9321 2013 swedish orphan biovitrum ab publ all rights reserved quick links terms of use & cookies all contacts follow us press releases news financial reports subscription service language english svenska name email i would like to subscribe to financial reports press releases opou t te webov str nky sobi spole nost sobi ji d le nenese odpov dnost za obsah ani funk nost internetov ch str nek jin ch subjekt . p ejete si opustit str nky ano ne